Fluorinated 2-Arylpropanoic Acids for Metabolic Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current compounds that inhibit CXCL8 and C5a-induced neutrophil chemotaxis and degranulation often suffer from metabolic instability and unwanted side effects due to hydrogen substitution, leading to reduced pharmacokinetic profiles and anti-inflammatory activity.
Innovation Solution
Introduction of a fluorine atom at the α position of 2-aryl-2-fluoropropanoic acids and their derivatives, which prevents racemization, enhances pharmacokinetics, and maintains biological activity while dissociating from unwanted metabolite effects, resulting in improved pharmacokinetic profiles and therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hydrogen substitution is used in 2-arylpropanoic acids, then metabolic stability is reduced, but introducing fluorine at the α position improves metabolic stability while maintaining biological activity
Solution Approach 1:
The patent applies parameter changes by substituting hydrogen with fluorine at the α position of 2-arylpropanoic acids. This chemical parameter change transforms the metabolic stability profile of the compound, preventing racemization and blocking metabolic pathways that lead to unwanted metabolites, while maintaining the desired biological activity against neutrophil chemotaxis and degranulation.
Solution Approach 2:
The patent converts the potential harm of fluorine substitution (which can alter pKa, chemical reactivity, and stability) into a benefit by strategically placing fluorine at the α position. This specific positioning prevents racemization and blocks metabolically labile sites, transforming what could be a source of instability into a mechanism for improving metabolic stability and reducing unwanted metabolite formation.
2Reliability
If fluorine is introduced at the α position of 2-arylpropanoic acids, then pharmacokinetic profile is improved, but traditional fluorine substitution may cause dramatic loss of anti-inflammatory activity
Solution Approach 1:
The patent applies parameter changes by introducing fluorine at the α position, which improves pharmacokinetic parameters such as half-life and volume of distribution. The specific positioning of fluorine at the α position, rather than other positions on the molecule, allows for improved pharmacokinetics while preserving the biological activity necessary for inhibiting neutrophil chemotaxis and degranulation.
Solution Approach 2:
The patent applies local quality by placing fluorine specifically at the α position of the 2-arylpropanoic acid structure. This localized modification affects specific properties (metabolic stability, racemization prevention) while leaving other parts of the molecule intact to maintain biological activity. The local fluorine substitution creates a differentiated effect that improves pharmacokinetics without sacrificing therapeutic efficacy.
3Object-generated harmful factors
If conventional compounds are used to inhibit neutrophil chemotaxis, then anti-inflammatory activity is achieved, but metabolic instability and unwanted side effects occur
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure through fluorine substitution at the α position. This change alters the metabolic stability parameter and prevents the formation of unwanted metabolites, while maintaining the ability to inhibit neutrophil chemotaxis and degranulation. The fluorinated compounds demonstrate both improved metabolic stability and preserved anti-inflammatory activity.
Solution Approach 2:
The patent converts the potential harm of structure modification into a benefit by using fluorine substitution to block metabolically labile sites. This transformation turns what could be a source of metabolic instability into a protective mechanism that enhances metabolic stability and reduces unwanted side effects, while maintaining therapeutic efficacy.
Data Source
AI summary
The present invention relates to (R,S) 2-aryl-2-fluoropropanoic acids, their single enantiomers (R) and (S), their derivatives amides and acylsulfonamides and to pharmaceutical compositions containing them, which are used in the prevention and treatment of tissue damage due to the exacerbated recruitment of polymorphonucleated neutrophils (PMN leukocytes) at inflammation sites. The present invention provides compounds for use in the treatment of psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bullous pemphigo, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and in the treatment of damages caused by ischemia and reperfusion.